Zalicus +43.5% AH; Epirus releases positive BOW015 data

A Phase 3 study on the efficacy and safety of Epirus' BOW015 rheumatoid arthritis drug relative to the currently-available Remicade "met its pre-specified statistical endpoint," and found "no meaningful differences observed in safety or immunogenicity."

Results from the open label testing phase, including "one year immunogenicity, one year safety, and long-term responder rates," are expected in Q3.

Epirus merger partner Zalicus (ZLCS) is responding quite well to the news.

Comments (6)
  • Jason Napodano, CFA
    , contributor
    Comments (1132) | Send Message
    I've been saying since the merger was announced, Epirus is way too cheap based on Zalicus market cap!


    11 Jun 2014, 05:34 PM Reply Like
  • Sedona6
    , contributor
    Comments (13) | Send Message
    Jason - With all due respect you've been wrong every step of the way, I enjoy your enthusiasm, and self promoting but you blew it with the prediction of Z160 and now you're attempting to put a positive spin on Epirus who opens up with a reverse split day one.


    I'll continue to follow you in hopes you get it right just once. Go buy some INO....that's a freebie from me.
    21 Jul 2014, 01:50 PM Reply Like
  • sikkabooyah
    , contributor
    Comments (457) | Send Message
    Jason, you're one of the last analysts in the world from whom I want to hear the words "I told you so".


    Thanks to their 2013 reverse split I'm still buried in ZLCS. Even today's 50% after-hours boost barely moves the needle, which remains firmly in the long wavelength end of the visible spectrum.


    I understand that small-cap biotechs don't promise anyone a rose garden and that investing in them is a sometime thing. I can live with their ups and downs but not the "I told you sos" from analysts who insist on playing Guys & Dolls' "Fugue for Tinhorns" long after the race has ended.
    11 Jun 2014, 05:57 PM Reply Like
  • Sedona6
    , contributor
    Comments (13) | Send Message
    Sikkabooyah -


    Are you still holding Epirus? I sold this company, they'll continue to decline all the way to $1 within six months; they have nothing to offer and it's obvious they just wanted a vehicle to get into NASDAQ - they'll rape it and run with the cash.


    Buy INO.....
    21 Jul 2014, 01:53 PM Reply Like
  • scruffyguy
    , contributor
    Comments (7) | Send Message
    Isn't this old news ?
    12 Jun 2014, 08:52 AM Reply Like
  • Sedona6
    , contributor
    Comments (13) | Send Message
    Epirus is no different then Zalicus. Hype, reverse splits, golden parachute clauses for their management.


    I voted against the merger because of the risk of a reverse split, Epirus did not disappoint; 10:1 R/S only pads the pockets of management.


    Long Zalicus holders are done, put out to pasture; and completely blindsided by the manipulation of the these types of companies. Sold Epirus and bought INO in hopes that this company can possibly make up for the horrific management of Zalicus / Epirus.
    21 Jul 2014, 01:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs